Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis
Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis and Clinically Isolated Syndrome
Sponsor: Albert Christian Ludolph, Prof.
Listed as NCT02671682, this NA trial focuses on Clinically Isolated Syndrome and Multiple Sclerosis and remains completed. Sponsored by Albert Christian Ludolph, Prof., it has been updated 12 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Oct 2019 — Jan 2021 [monthly]
Completed NA
-
Apr 2019 — Oct 2019 [monthly]
Completed NA
Phase: None → NA
▶ Show 7 earlier versions
-
Mar 2019 — Apr 2019 [monthly]
Completed
Status: Unknown Status → Completed
-
Nov 2018 — Mar 2019 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jun 2018 — Nov 2018 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Albert Christian Ludolph, Prof.
For direct contact, visit the study record on ClinicalTrials.gov .